Source Pravda.Ru

Japan approves Roche's cancer drug Herceptin

Japan 's health authorities have approved Roche's cancer drug Herceptin for the treatment of HER2-positive breast cancer.

HER2-positive breast cancer affects approximately 20 to 30 percent of women with breast cancer, the most common cancer among women worldwide.

Each year more than 1 million new cases of breast cancer are diagnosed worldwide, and nearly 400,000 people will die of the disease annually.

Herceptin, a humanized antibody, designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential, is marketed by Roche's subsidiary in Japan.

F. Hoffmann–La Roche Ltd. is a Swiss global health-care company which operates world-wide under two divisions: Pharmaceuticals and Diagnostics. It belongs to the Roche Holding AG.

The headquarters are in Basel and the company has many sites around the world - including: Nutley, Palo Alto, Pleasanton, Branchburg, Indianapolis, Florence in the US, Welwyn Garden City in the UK, Mannheim, Penzberg in Germany, and Shanghai in China .

The company also owns a majority of the American biotechnology company Genentech and the Japanese biotechnology company Chugai Pharmaceuticals.

In an exclusive interview with Pravda.Ru, US filmmaker talks to Edu Montesanti on the presidential elections in the Caribbean country, and its importance to Latin America. "The left will come back in Latin America, more likely sooner than later," says Oliver Stone

Exclusive Interview: Oliver Stone on Venezuelan Election

In an exclusive interview with Pravda.Ru, US filmmaker talks to Edu Montesanti on the presidential elections in the Caribbean country, and its importance to Latin America. "The left will come back in Latin America, more likely sooner than later," says Oliver Stone

Exclusive Interview: Oliver Stone on Venezuelan Election